A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

August 7, 2023

Study Completion Date

August 7, 2023

Conditions
Diabetic Retinopathy
Interventions
DRUG

BI 765128

BI 765128

OTHER

Sham comparator

Sham comparator

Trial Locations (25)

1006

Riga East University Hospital, Riga

5000

Adelaide Eye and Retina Centre, Adelaide

7008

Hobart Eye Surgeons, Hobart

16507

Erie Retina Research, LLC, Erie

19107

Mid Atlantic Retina, Philadelphia

21740

Cumberland Valley Retina Consultants, PC., Hagerstown

28040

Hospital Clínico San Carlos, Madrid

45219

Meridian Clinical Research, LLC, Cincinnati

50009

Hospital Miguel Servet, Zaragoza

77384

Retina Consultants of Texas, The Woodlands

77401

Retina Consultants of Texas, Bellaire

78705

Austin Research Center for Retina, PLLC, Austin

78750

Austin Clinical Research, LLC, Austin

93309

California Retina Consultants, Bakersfield

94598

Bay Area Retina Associates - Walnut Creek, Walnut Creek

95825

Retinal Consultants Medical Group, Sacramento

2333 ZA

Leids Universitair Medisch Centrum (LUMC), Leiden

08025

Hospital Dos de Maig, Barcelona

08035

Hospital Vall d'Hebron, Barcelona

BS1 2LX

Bristol Eye Hospital, Bristol

L7 8XP

Royal Liverpool University Hospital, Liverpool

EC1V 2PD

Moorfields Eye Hospital, London

NW10 7NS

Central Middlesex Hospital, London

OX3 9DU

Oxford Eye Hospital, Oxford

SR2 9HP

Sunderland Eye Infirmary, Sunderland

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04919499 - A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment | Biotech Hunter | Biotech Hunter